Betta Pharmaceuticals Co Ltd (Betta Pharmaceuticals) discovers, develops, and supplies drugs for the treatment of cancer and diabetes. Its products include icotinib hydrochloride, an orally administered small-molecule, a reversible tyrosine kinase inhibitor for treating locally advanced or metastatic non-small cell lung cancer; and ensartinib hydrochloride capsules to treat ALK-mutated advanced non-small cell lung cancer. The company has also developed beantine, a macromolecular biological product for the treatment of recurrent non-small lung cancer. Betta Pharmaceuticals is developing its pipeline with small and macromolecule products for multiple cancer treatments. The company operates research and development centers in Hangzhou and Beijing, China and San Diego, the US. Betta Pharmaceuticals is headquartered in Hangzhou, Zhejiang, China.
Headquarters
China
Address
No. 589 Hongfeng Road, Yuhang Economic Development Zone, Hangzhou, Zhejiang, 311100
Website
www.bettapharma.com
Telephone
86 571 89265665
No of Employees
1,961
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300558 (SHE)
Revenue (2021)
$353.2M
5.8%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-62%
(2021 vs 2020)
Market Cap*
$2.2B
Net Profit Margin (2021)
XYZ
-64.1%
(2021 vs 2020)
* As of and is in US$
Betta Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Icotinib |
| Ensartinib |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In January, the company received approval from the State Food and Drug Administration for the clinical trial application of BPI-520105 tablets. |
| 2023 | Regulatory Approval | In February, the company received the notice of drug clinical trial approval issued by the State Drug Administration. |
| 2023 | Others | In January, the company's BPB-101 double antibody injection clinical trial application accepted by the State Drug Administration. |
Competitor Comparison
| Key Parameters | Betta Pharmaceuticals Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Cachet Pharmaceutical Co Ltd | Walvax Biotechnology Co Ltd | Beijing SL Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Hangzhou | Shanghai | Beijing | Kunming | Beijing |
| State/Province | Zhejiang | Shanghai | Beijing | Yunnan | Beijing |
| No. of Employees | 1,961 | 40,370 | 2,294 | 2,388 | 757 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ding Lieming | Chairman; General Manager; Chief Executive Officer | Executive Board | 2013 | 60 |
| Tong Jia | Director; Chief Executive Officer | Executive Board | 2021 | 46 |
| Fan Jianxun | Director; Vice President; Chief Financial Officer | Executive Board | 2021 | 52 |
| Wan Jiang | Senior Vice President; Director; Chief Operating Officer | Executive Board | 2017 | 55 |
| Jiabing Wang | Director; Senior Vice President | Executive Board | 2019 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward